China's Type 2 Diabetes Drug Market Will More than Triple by 2012

Wednesday, May 28, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

WALTHAM, Mass., May 28 Decision Resources, one of theworld's leading research and advisory firms focusing on pharmaceutical andhealthcare issues, forecasts that the Chinese type 2 diabetes drug market willmore than triple by 2012. According to the new Emerging Markets reportentitled Type 2 Diabetes in China, this growth will be fueled by increasedaccess to health insurance, greater patient spending power and more aggressivetreatment practice, leading to increased usage of newer agents such as theinsulin analogues. Additionally, the number of prevalent cases of type 2diabetes in China is among the highest in the world -- 62.5 million cases in2007 -- a number that rivals that of the United States, Europe and Japancombined (48.5 million cases). The high prevalence rate in China reflects anaging population and urbanization-associated risk factors, such as diet andlack of physical activities.

"The Chinese government and medical associations are promoting guidelinespublished by the American Diabetes Association, the World Health Organizationand the Chinese Society of Diabetes," said Victor Li, Ph.D., analyst atDecision Resources. "All guidelines advocate earlier and more-aggressiveinterventions in type 2 diabetes patients. We forecast that the patientpopulation treated with polypharmacy will nearly double between 2007 and2012."

The report also finds that three new type 2 diabetes agents with novelmechanisms -- Eli Lilly/Amylin's Byetta, Merck's Januvia and Novartis'sGalvus -- are expected to launch in China by 2012. The combined sales of thesethree agents will surpass $270 million by 2012. However, the high cost of manyantidiabetic therapies, particularly Western-branded drugs, is a major barrierto effective management of type 2 diabetes in China. Patient ability to payfor medications influences physician prescribing habits, particularlyprescription of newer drugs such as the peroxisome proliferator-activatedreceptor (PPAR)-gamma agonists and the insulin analogues, which are notreimbursed or are only partially reimbursed in some provinces.

About Emerging Markets - China

Emerging Markets - China is the first and only syndicated report seriesfocusing on high-growth emerging markets with comprehensive disease-specificanalysis. With these reports, biopharmaceutical companies can accomplish thefollowing:

About Decision Resources

Decision Resources, Inc. ( is a world leader inresearch publications, advisory services, and consulting designed to helpclients shape strategy, allocate resources, and master their chosen markets.Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.-- More accurately assess the commercial opportunity for Western brands in key pharmaceutical markets of China -- Beijing, Shanghai, Guangzhou -- and in the high-growth second-tier markets of Tianjin, Wuhan, Nanjing, Hangzhou, and Jinan. -- Understand the physician treatment patterns and drivers of choice in key first- and second-tier cities based on primary research. -- Gain a clear perspective of the Chinese five-year market forecast at the drug level, broken out by urban and rural areas, and by sales from multinational and Chinese-based companies.

SOURCE Decision Resources, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store